Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy

British Journal of Cancer

Volumn 105, Issue 12, 2011, Pages 1825-1829

  Balakrishnan, A ^a   Ravichandran, D ^a  

^a LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast cancer; Letrozole

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; COMORBIDITY; DRUG WITHDRAWAL; FEMALE; FEMUR FRACTURE; FOLLOW UP; FRAIL ELDERLY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PRIORITY JOURNAL; SENESCENCE; SPINE FRACTURE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WRIST FRACTURE; BREAST TUMOR; FRACTURE; MIDDLE AGED; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; NITRILES; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 84856012992     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.470     Document Type: Article

References (45)

1. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2630-2637
2. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139 (Pubitemid 34694019)
3. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Kurtz J, Sappino AP, Vlastos G (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21: 3580-3587 (Pubitemid 46594049)
4. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95: 2006-2016 (Pubitemid 35222182)
5. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative 'Arimidex' Compared to Tamoxifen (PROACT) trial. Cancer 106: 2095-2103 (Pubitemid 43673229)
6. Cheung KL, Wong AW, Parker H, Li VW, Winterbottom L, Morgan DA, Ellis IO (2008) Pathological features of primary breast cancer in the elderly based on needle core biopsies-a large series from a single centre. Crit Rev Oncol Hematol 67: 263-267
7. Chow LW, Yip AY, Loo WT, Lam CK, Toi M (2008) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111: 13-17
8. Crivellari D, Sun Z, Coates AS, Price KN, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26: 1972-1979
9. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11: 1135-1141
10. Dixon JM, Love CD, Bellamy CO, Cameron DA, Leonard RC, Smith H, Miller WR (2001) Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66: 191-199 (Pubitemid 32675021)
11. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR (2000) The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6: 2229-2235 (Pubitemid 30399188)
12. Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB, Miller WR (2009) Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 113: 145-151
13. Early Breast Cancer Trialists' Collaborative Group (2001) Tamoxifen for early breast cancer. Cochrane Database Syst Rev (Online) 1: CD000486
14. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
15. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12: 1527-1532 (Pubitemid 34065880)
16. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, Deschryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29: 2342-2349
17. Geisler J (2011) Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole-of clinical importance? Br J Cancer 104: 1059-1066
18. Hind D, Wyld L, Reed MW (2007) Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. Br J Cancer 96: 1025-1029 (Pubitemid 46608304)
19. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Janicke F, Bastert G, Kiesel L, Wackwitz B, Paepke S (2008) Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 8: 62
20. Lilienfeld AM (1963) The epidemiology of breast cancer. Cancer Res 23: 1503-1513
21. Louwman WJ, Voogd AC, van Dijck JA, Nieuwenhuijzen GA, Ribot J, Pruijt JF, Coebergh JW (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19: 97-106
22. Mathew J, Agrawal A, Asgeirsson KS, Buhari SA, Jackson LR, Cheung KL, Robertson JF (2009) Primary endocrine therapy in locally advanced breast cancers-the Nottingham experience. Breast Cancer Res Treat 113: 403-407
23. Mauriac L, Debled M, Durand M, Floquet A, Boulanger V, Dagada C, Trufflandier N, MacGrogan G (2002) Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 13: 293-298 (Pubitemid 34704983)
24. Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G (2010) Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat 121: 399-411
25. Milla-Santos A, Milla L, Calvo N, Portella J, Rallo L, Casanovas JM, Pons M, Rodes J (2004) Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res 24: 1315-1318 (Pubitemid 38624981)
26. Miller WR, Larionov A (2010) Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res 12: R52
27. Miller WR Larionov A, Anderson TJ, Evans DB, Dixon JM (2010) Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J; e-pub ahead of print 10 August 2010
28. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606 (Pubitemid 32451796)
29. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361: 766-776
30. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE (2008) Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26: 1956-1964
31. Mustacchi G, Mansutti M, Sacco C, Barni S, Farris A, Cazzaniga M, Cozzi M, Dellach C (2009) Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. Ann Oncol 20: 655-659
32. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767
33. NHS Cancer Screening Programmes. http://www.cancerscreening.nhs.uk/ breastscreen/all-breast-cancer-report.pdf
34. Okunade G, Green AR, Ying M, Agrawal A, Paish EC, Aleskandrany M, Winterbottom L, Hassell K, Morgan DA, Ellis IO, Cheung KL (2009) Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. Crit Rev Oncol Hematol 72: 76-82
35. Olson Jr JA, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight Jr GS, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ (2009) Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg 208: 906-914; discussion 915-916
36. Preece PE Wood RA, Mackie CR, Cuschieri A (1982) Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res ed) 284: 869-870 (Pubitemid 12185510)
37. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Lang I, Smith I, Gelber RD, Goldhirsch A, Coates AS (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20: 1489-1498
38. Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J (2010) Systematic review of aromatase inhibitors in the firstline treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 123: 9-24
39. Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120: 104-110 (Pubitemid 24027550)
40. Semiglazov V, Kletsel A, Semiglazov V, Zhiltzova E, Ivanov V, Dashyan G, Bozhok A, Melnikova O, Paltuev R, Berstein L (2005) Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) [abstract]. J Clin Oncol 23(16S): 530
41. Smith IE Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23: 5108-5116 (Pubitemid 46224019)
42. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757 (Pubitemid 43016814)
43. Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H (2011) Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci 102: 858-865
44. Traa MJ, Meijs CM, de Jongh MA, van der Borst EC, Roukema JA (2011) Elderly women with breast cancer often die due to other causes regardless of primary endocrine therapy or primary surgical therapy. Breast 20: 365-369
45. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100: 2028-2033